help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kautzky-Willer, A.
Right arrow Articles by Wagner, O. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kautzky-Willer, A.
Right arrow Articles by Wagner, O. F.
The Journal of Clinical Endocrinology & Metabolism Vol. 82, No. 12 4117-4121
Copyright © 1997 by The Endocrine Society


Original Studies

Persistent Elevation and Metabolic Dependence of Circulating E-Selectin after Delivery in Women with Gestational Diabetes Mellitus

A. Kautzky-Willer, P. Fasching, B. Jilma, W. Waldhäusl and O. F. Wagner

Department of Medicine III, Division of Endocrinology and Metabolism (A.K-W., P.F., W.W.), Department of Clinical Pharmacology (B.J.) and Department of Medical and Chemical Laboratory Diagnostics (O.F.W.), University of Vienna, Austria

Address all correspondence and requests for reprints to: Oswald F Wagner, Department of Clinical and Chemical Laboratory Diagnostics, University of Vienna, Währinger Gürtel 18–20, 1090 Vienna, Austria.


    Abstract
 Top
 Abstract
 Introduction
 Subjects and Methods
 OGTT
 Statistical analyses
 Results
 Discussion
 References
 
The increased risk of premature atherosclerosis in noninsulin-dependent diabetes mellitus (NIDDM) might be related in part to augmented expression of endothelial adhesion molecules (AMs). So far it is, however, unknown whether increased circulating (c) AMs in NIDDM are only a consequence of this disease or also involved in its sequelae.

To determine the presence of cAMs in a population at increased risk for subsequent development of NIDDM, we analyzed fasting and postprandial [oral glucose tolerance test (OGTT): 100 g] serum concentrations of circulating E-selectin, vascular cell adhesion molecule-1 (cVCAM-1), and intercellular adhesion molecule-1 (cICAM-1) in pregnant women with either gestational diabetes (GDM) or normal glucose tolerance (NT) before and after delivery vs. nonpregnant healthy women (C). During pregnancy cE-selectin and cVCAM-1 were elevated in both GDM and NT vs. nonpregnant females (P < 0.01 vs. C). Following delivery, all GDM females regained normal glucose tolerance according to OGTT criteria, but showed slightly higher postprandial [area under the curve (AUC)180 min] glycemia and HbA1c values than nonpregnant healthy women (P < 0.05), indicating persisting subtle abnormalities in carbohydrate metabolism. cE-selectin and cVCAM-1 remained increased in GDM (P < 0.01 vs.C) after delivery, but fell to normal in NT (P < 0.05 before vs. after delivery). Furthermore, a correlation was seen in GDM females between cE-selectin and HbA1c (P < 0.005), fasting glucose (P < 0.01), and insulin (P < 0.05) as well as postprandial (AUC180 min) glucose and insulin concentrations (P < 0.05) during OGTTs, both before and after delivery. ICAM-1, however, did not differ significantly between groups.

In summary, GDM is characterized by persistently raised levels of cE-selectin and cVCAM-1 12 weeks after delivery. Whether these persistent elevations of cE-selectin and cVCAM-1 reflect early vascular injury or represent a risk factor for atherosclerosis in women at increased risk for NIDDM remains to be determined.


    Introduction
 Top
 Abstract
 Introduction
 Subjects and Methods
 OGTT
 Statistical analyses
 Results
 Discussion
 References
 
THE adhesion molecules (AMs) E-selectin, vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1) are supposed to play a major role in the pathogenesis of vascular disease (1, 2). It is assumed that their endothelial expression triggers adhesion of monocytes to the endothelium, an early step in the development of atherosclerosis (1, 3). Serum concentrations of circulating (c) AMs may reflect endothelial activity and/or damage (4), because endothelial cells release soluble forms of AMs in correlation to their surface expression (3, 5). The origin of individual cAMs differs. Surface expression of E-selectin is completely and that of VCAM-1 rather specific for endothelium. In contrast, the origin of ICAM-1 is widespread and thus does not allow conclusions on the endothelial state.

Noninsulin-dependent diabetes mellitus (NIDDM) is associated with an increased risk of premature atherosclerosis (6, 7). Recently, increased serum concentrations of AMs have been observed in NIDDM (8, 9, 10, 11). In some (8, 9, 10) but not all (11) of these studies a potential effect of glycemic control on cE-selectin was postulated. These controversial observations might be because of cross-sectional study design and heterogeneity of patients for the presence of diabetic complications and additional atherogenic risk factors.

Pregnancy is a hyperinsulinemic state, which may transgress into impaired glucose tolerance if insulin secretion is unable to compensate for pregnancy-associated insulin resistance (12, 13, 14). Although most women with gestational diabetes mellitus (GDM) regain normal glucose tolerance after delivery, many of them feature subtle disturbances in postpartum glucose homeostasis and are at high risk of later developing NIDDM (13, 14, 15, 16). Thus, GDM can be regarded a model for early NIDDM (16).

To investigate the hypothesis of a dependence of cE-selectin on glucose metabolism in the absence of coexistent atherosclerosis and additional atherogenic risk factors, cAMs were studied in GDM and pregnant women with normal glucose tolerance (NT) before and after delivery as well as in healthy nonpregnant women (C).


    Subjects and Methods
 Top
 Abstract
 Introduction
 Subjects and Methods
 OGTT
 Statistical analyses
 Results
 Discussion
 References
 
None of the subjects [GDM, NT, or control (C)] studied had a family history of diabetes, was taking any medication, or had any known disease. All women had normal renal and liver function, were negative for islet cell antibodies, and free of manifest infections, hypertension, hyperlipidemia, and obesity (Table 1Go). Cesarean section or any other surgical intervention were exclusion criteria. No pregnant woman had signs of placental insufficiency as documented by Doppler velocimetry and pH of umbilical cord. All females delivered healthy children appropriate for gestational age. The nonpregnant control subjects (C) were members of the paramedical staff. GDM was diagnosed by a 100-g oral glucose tolerance test (OGTT) following the criteria of O’Sullivan and of the 3rd International Workshop on Gestational Diabetes Mellitus (17, 18). A positive 100-g OGTT was defined as two or more values above 5.8 mmol/L in the fasting state, 10.6 mmol/L at 1 h, 9.2 mmol/L at 2 h, and/or 8.1 mmol/L at 3 h after glucose loading. The groups were matched for age and (preconceptual) body mass index (BMI). There were no significant differences in weight gain during pregnancy (12.0 ± 2.0 kg in GDM and 14.8+1.9 kg in NT) or BMI at term (30.3 + 1.8 vs. 29.0 + 0.9 kg/m2) between GDM and NT. Three months after delivery, BMI decreased to the preconceptual one in both groups (Table 1Go). Women with GDM, who were reinvestigated for reclassification of glucose tolerance after delivery using a 75-g standard OGTT (WHO criteria; Ref.19), featured normal glucose tolerance. In addition, 100-g OGTTs were repeated 12 weeks after delivery for comparison of glucose and insulin release vs. the pregnant state. cAMs were determined both in the fasting state and 180 min after glucose loading (100 g). The protocol has been approved by the ethics committee of the University of Vienna. Informed consent was obtained from all subjects studied.


View this table:
[in this window]
[in a new window]
 
Table 1. Characteristics of pregnant women with GDM and those with normal glucose tolerance (NT) at gestational week 28 and 12 weeks after delivery (GDMpost and NTpost) vs. nonpregnant healthy females (C)

 

    OGTT
 Top
 Abstract
 Introduction
 Subjects and Methods
 OGTT
 Statistical analyses
 Results
 Discussion
 References
 
Venous blood samples were obtained for measurement of serum glucose, insulin, and C-peptide fasting and at 10, 20, 30, 60, 90, 120, 150, and 180 min after oral 100-g glucose loading in the morning after an overnight fast. Blood was rapidly centrifuged, and glucose immediately determined by glucose oxidase method with an automated glucose analyzer (Beckman, Fullerton, CA). Samples for measurement of insulin and C-peptide were frozen at -20 C and later determined by commercially available RIAs (Serono, Freiburg, Germany and CIS, Gif-Sur-Yvette, France). Glycated hemoglobin (HbA1c; upper normal range 5.8%) was quantified by on-line high-pressure liquid chromatography (HPLC; C-R4A Chromatopac, Shimadzu, Kyoto, Japan) from capillary blood.

Serum samples for determination of cAMs were stored at -80 C and analyzed in duplicate by commercially available enzyme-linked immunosorbent assays (British Bio-Technology Product Ltd., Abdington, UK) as described previously (20) with both inter- and intraassay coefficients of variation being <6%.


    Statistical analyses
 Top
 Abstract
 Introduction
 Subjects and Methods
 OGTT
 Statistical analyses
 Results
 Discussion
 References
 
Results are expressed as means and SEM unless otherwise designated. Group differences were determined by ANOVA; correlation coefficients were calculated by linear regression analysis. In addition, multiple regression analysis was computed (STAT Software), to determine independent regulators of cE-selectin levels. Differences within GDM and NT before vs. after delivery were calculated by the paired Student’s t test. A P value <0.05 was considered significant.


    Results
 Top
 Abstract
 Introduction
 Subjects and Methods
 OGTT
 Statistical analyses
 Results
 Discussion
 References
 
Fasting (Fig. 1Go) and postprandial serum concentrations of cE-selectin and cVCAM-1 were elevated (P < 0.05) in GDM (fasting: cE-selectin +128%, cVCAM-1 +63%; postprandially: +110%, +55%, respectively) and NT (fasting: cE-selectin +145%, cVCAM-1 +69%; postprandially: +107%, +59%, respectively) compared with nonpregnant females (C), whereas fasting and stimulated cICAM-1 did not differ between groups. There were no differences between fasting and stimulated (180 min, 100-g OGTT) cAMs in each group.



View larger version (17K):
[in this window]
[in a new window]
 
Figure 1. cE-selectin, cVCAM-1, and cICAM-1 in pregnant women with GDM and those with normal glucose tolerance (NT) before and after delivery as well as in nonpregnant control females (C); shown for each single individual. #, P < 0.01 vs. C (ANOVA). *, P < 0.05, NT before vs. after delivery (paired Student’s t test).

 
Whereas in NT fasting and postprandial cE-selectin and cVCAM-1 decreased 12 weeks after delivery (P < 0.05) to the normal range of healthy women, both cAMs remained unchanged in GDM postpartum (P < 0.01 vs. C) (Fig. 2Go).



View larger version (26K):
[in this window]
[in a new window]
 
Figure 2. Relationship between cE-selectin and HbA1c values (A), fasting plasma glucose concentrations (B), and AUCs during OGTT(AUC180 min; 100 g) for glucose (C) and insulin (D) in women with GDM during pregnancy (• and solid line) and 3 months after delivery ({square} and dotted line).

 
During pregnancy, mean fasting glucose was higher (P < 0.05) in GDM than in NT, and fasting serum concentrations of insulin (P < 0.01) and C-peptide (P < 0.05) were elevated in both GDM and NT vs. nonpregnant C (Table 1Go). Twelve weeks after delivery, serum insulin and C-peptide values fell (P < 0.05), though insulin concentrations still tended to be higher in GDM (ns vs. C). Mean HbA1c values were within the normal range in GDM (5.2 + 0.2%), but slightly higher than those in NT (4.6 ± 0.1%) and C (4.5 ± 0.1%) during pregnancy and tended to decrease 3 months after preg-nancy (Table 1Go). Postprandial [total area under the curve (AUC180 min) glucose (glucoseAUC) and insulin (insulinAUC) concentrations are shown in Table 1Go. Despite comparable basal and (total) postprandial insulin concentrations, the insulin levels 30 min after glucose loading were significantly (P < 0.05) lower in GDM than NT, indicating a secretion deficit in the early phase in GDM both during pregnancy as well as 12 weeks after delivery.

In GDM, cE-selectin correlated with fasting glucose, HbA1c, glucoseAUC, insulinAUC (Fig. 2Go), and fasting insulin (r = 0.5, P = 0.047). In the entire group of females (GDM, NT, and C), cE-selectin also correlated with fasting glucose (r = 0.5, P < 0.05), insulin (r = 0.63, P < 0.02), glucoseAUC (r = 0.77, P < 0.0025), and insulinAUC (r = 0.63, P < 0.02), as well as with HbA1c (r = 0.64, P < 0.03). Multiple regression analysis selected only glucose but not insulin levels as an independent predictor of cE-selectin levels (P < 0.05).


    Discussion
 Top
 Abstract
 Introduction
 Subjects and Methods
 OGTT
 Statistical analyses
 Results
 Discussion
 References
 
The elevations of cE-selectin and cVCAM-1 in GDM and NT vs. matched nonpregnant control women might suggest that such increase is characteristic for pregnancy or the insulin resistance in pregnancy. The responsible mechanisms for that phenomenon however remain to be elucidated. Because no evidence of VCAM-1 and E-selectin expression has been found in placentae from normal pregnancies as well as from those complicated by preeclampsia or intrauterine growth retardation (21), the increase in cE-selectin and cVCAM-1 could be influenced by the endocrine changes related to pregnancy.

In accordance with others reporting normalization of glucose tolerance in 90% of the women with former GDM postpartum (22), all GDMs had returned to normal glucose tolerance according to established OGTT criteria. Interestingly, contrary to NT, where cE-selectin and cVCAM-1 fell to normal after delivery, in former GDMs these cAMs remained elevated. Although it cannot be excluded that cE-selectin and cVCAM-1 might decrease to normal after a longer follow-up period in these subjects also, it is remarkable that their normalization within 3 months after delivery appeared in all women with normal glucose tolerance, whereas they remained unchanged in women with GDM. Because cE-selectin and cVCAM-1 even tended to increase (ns) in GDM by approximately 8–15% 12 weeks after delivery, ongoing endothelial dysfunction might be self-perpetuating after its initiation during pregnancy. In contrast to the endothelial-specific cAMs E-selectin and VCAM-1, cICAM-1, which is of nonspecific origin, did not differ between or within any group.

It has to be emphasized that a homogeneous group of GDM females without additional risk factors for NIDDM and atherosclerosis has been selected for evaluation of a relation of cAMs to glucose metabolism. Although the group might represent a subset of GDM subjects at lower risk for later development of NIDDM, these women, nevertheless, featured postpartum persisting metabolic abnormalities commonly described in former GDM such as mild hyperglycemia, slightly elevated basal insulin concentrations, and a defect in acute glucose-stimulated insulin release (13, 15, 23).

Increased cAM levels in general may reflect both changes in synthesis/release and clearance. Data on clearance sites and rates of cAMs are not available so far. However, in young women with normal kidney and liver function, increased levels are expected to primarily reflect synthesis/release (4).

In contrast to NIDDM, advanced atherosclerosis is not likely in young females lacking additional risk factors. However, microvascular dysfunctions can be present in otherwise healthy prediabetic subjects with mild fasting hyperglycemia and hyperinsulinemia related to insulin resistance (24) and therefore might account for the observed increase in E-selectin and VCAM-1.

A potential association between a high risk to develop NIDDM and cE-selectin is supported by the strong relation between cE-selectin and metabolic control in GDM subjects (Fig. 2Go). In a multiple regression analysis, E-selectin was independently related to glycemia and only secondarily to associated basal and total (basal and delayed postprandial) insulin release. The correlation between E-selectin and plasma glucose concentrations in the entire group of females might further support the hypothesis of a possible effect of chronic glycemia on cE-selectin expression. Although glucose has been shown to increase monocyte binding to human endothelial cells in vitro (25), it failed to directly stimulate E-selectin expression in cultured endothelial cells (26). As recently proposed by Cominacini and co-workers (10), glycemia might in vivo affect E-selectin plasma concentrations through its effect on oxidative stress.

Although cVCAM-1 was not directly related to glucose metabolism in GDM or NIDDM, additional metabolic aberrations as increased formation of advanced glycosylation end products may add to its increase (27).

The finding of elevated cE-selectin and cVCAM-1 in women at risk for NIDDM gains further relevance by the recently described direct angiogenic effect of both soluble E-selectin and VCAM-1 (28), which may also play an important role in the development of diabetic retinopathy and nephropathy. Indeed, higher cVCAM levels have been found in insulin- dependent diabetic patients with retinopathy and nephropathy than in those without these complications (29).

Although the relevance of elevated soluble AMs in vascular disease is not established until now, three models for a role of elevated cE-selectin and cVCAM-1 may be considered. First, elevated serum levels could reflect increased expression of the respective cAMs on the endothelial surface, thereby potentially stimulating monocyte recruitment into the vascular wall. Secondly, increased cAMs may themselves induce angiogenesis. Third, increased cAMs may simply be the result of early vascular abnormalities in GDM and therefore represent a consequence rather than a potential cause of early vascular lesions. Further longitudinal studies will be necessary to thoroughly investigate the behavior of cAMs and the potential relation of cAMs to vascular and metabolic changes in women with a history of GDM.

Received December 5, 1996.

Revised March 14, 1997.

Revised June 16, 1997.

Accepted August 19, 1997.


    References
 Top
 Abstract
 Introduction
 Subjects and Methods
 OGTT
 Statistical analyses
 Results
 Discussion
 References
 

  1. Van der Wal AC, Das PK, Tigges AJ, Becker AE. 1992 Adhesion molecules on the endothelium and mononuclear cells in human atherosclerotic lesions. Am J Pathol. 141:1427–1433.[Abstract]
  2. Blann AD, Mc Collum CN. 1994 Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemost. 72:151–154.[Medline]
  3. Faggiotto A, Ross R, Harker L. 1984 Studies of hypercholesterolemia in the nonhuman primate. Atherosclerosis. 4:323–340.
  4. Gearing AJH, Newman W. 1993 Circulating adhesion molecules in disease. Immunol Today. 14:506–512.[CrossRef][Medline]
  5. Pigott R, Dillon LP, Hemingway IH, Gearing AJH. 1992 Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial. Biochem Biophys Res Comm. 187:584–589.[CrossRef][Medline]
  6. Pyrola K. 1991 Hyperinsulinemia as predictor of atherosclerotic vascular disease; epidemiological evidence. Diabete-Metab. 17:87–92.
  7. Yamamoto A, Yamamur T, Kawaguchi A, Kameda K, Matsuzawa Y. 1991 Triglycerides and glucose intolerance as a risk factor for coronary heart disease. Am J Cardiol. 78:185–93.
  8. Fasching P, Waldhäusl W, O.F. Wagner. 1996 1996 Elevated circulating adhesion molecules in non-insulin-dependent diabetes mellitus—potential mediators in diabetic macroangio-pathy. Diabetologia. 39:1242–1244.
  9. Cominacini L, Pasini AF, Garbin U, et al. 1995 Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic control. Diabetologia. 38:1122–1124.[Medline]
  10. Cominacini L, Pasini AF, Garbin U, et al. 1997 E-Selectin plasma concentration is influenced by glycemic control in NIDDM patients: possible role of oxidative stress. Diabetologia. 40:584–589.[CrossRef][Medline]
  11. Steiner M, Reinhardt KM, Krammer B, Blann AD. 1994 Increased levels of soluble adhesion molecules in type II (non-insulin-dependent) diabetes mellitus are independent of glycemic control. Thromb Haemost. 72:979–984.[Medline]
  12. Kühl C. 1991 Insulin secretion and insulin resistance in pregnancy and GDM: implications for diagnosis and management. Diabetes. 40[Suppl 2]:18–24.
  13. Ryan EA, Imes Sh, Liu D, et al. 1995 Defects in insulin secretion and action in women with a history of gestational diabetes. Diabetes. 44:505–551.
  14. Buchanon TA, Catalano PM. 1995 The pathogenesis of gestational diabetes mellitus: implications for diabetes following pregnancy. Diab Rev. 3:584–601.
  15. Kjos SL, Peters RX, Xiang A, Henry OA, Motoro M, Buchanon TA. 1995 Predicting future diabetes in latino women with gestational diabetes. Utility of early postpartum glucose tolerance testing. Diabetes. 44:586–591.[Abstract]
  16. Ramus RM, Kitzmiller JL. 1994 Diagnosis and management of gestational diabetes and other categories of glucose tolerance. Diab Rev. 2:43–52.
  17. Metzger BE. 1991 Summary and recommendations of the Third International Workshop Conference on Gestational Diabetes Mellitus. Diabetes. 40[Suppl 2]:197–201.
  18. National Diabetes Data Group. 1979 Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 28:1039–57.[Medline]
  19. World Health Organisation. 1985 Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org. Tech. rep. Ser., no. 727.
  20. Jilma B, Eichler HG, Breiteneder H, et al. 1994 Effects of 17ß-estradiol on circulating adhesion molecules. J Clin Endocrinol Metab. 79:1619–1624.[Abstract]
  21. Lyall F, Greer IA, Boswell F, Young A, Macara LM, Jeffers MD. 1995 Expression of cell adhesion molecules in placentae from pregnancies complicated by pre-eclampsia and uterine growth retardation. Placenta. 16:579–587.[CrossRef][Medline]
  22. Jovanovic-Peterson L. 1995 The diagnosis and management of gestational diabetes mellitus. Clinical Diabetes. 32–39.
  23. Kautzky-Willer A, Thomaseth K, Ludvik B, et al. 1997 Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes. Diabetes. 46:607–614.[Abstract]
  24. Jaap AJ, Shore AC, Tooke JE. 1997 Relationship of insulin resistance to microvascular dysfunction in subjects with fasting hyperglycemia. Diabetologia. 40:238–243.[CrossRef][Medline]
  25. Kim JA, Berliner JA, Natarajan RD, Nadler JL. 1994 Evidence that glucose increases monocyte binding to human aortic endothelial cells. Diabetes. 43:1103–1107.[Abstract]
  26. Baumgartner-Parzer SM, Wagner L, Pettermann M, Gessl A, Waldhäusl W. 1995 Modulation by high glucose of adhesion molecule expression in cultured endothelial cells. Diabetologia. 38:1367–1370.[Medline]
  27. Schmidt AM, Hori O, Chen JX, et al. 1995 Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest. 96:1365–1403.
  28. Koch AE, Halloran MM, Haskall CJ, Shah MR, Polverini PJ. 1995 Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature. 376:517–519.[CrossRef][Medline]
  29. Fasching P, Veitl M, Rohac M, et al. 1996 Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin-dependent diabetes mellitus (IDDM). J Clin Endocrinol Metab. 81:4313–4317.[Abstract]



This article has been cited by other articles:


Home page
Diabetes CareHome page
J. L. Kitzmiller, L. Dang-Kilduff, and M. M. Taslimi
Gestational Diabetes After Delivery: Short-term management and long-term risks
Diabetes Care, July 1, 2007; 30(Supplement_2): S225 - S235.
[Full Text] [PDF]


Home page
Diabetes CareHome page
S. Mustafa, T. Vukovich, T. Prikoszovich, C. Winzer, B. Schneider, H. Esterbauer, O. Wagner, and A. Kautzky-Willer
Haptoglobin Phenotype and Gestational Diabetes
Diabetes Care, September 1, 2004; 27(9): 2103 - 2107.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
C. Winzer, O. Wagner, A. Festa, B. Schneider, M. Roden, D. Bancher-Todesca, G. Pacini, T. Funahashi, and A. Kautzky-Willer
Plasma Adiponectin, Insulin Sensitivity, and Subclinical Inflammation in Women With Prior Gestational Diabetes Mellitus
Diabetes Care, July 1, 2004; 27(7): 1721 - 1727.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J. Calles-Escandon and M. Cipolla
Diabetes and Endothelial Dysfunction: A Clinical Perspective
Endocr. Rev., February 1, 2001; 22(1): 36 - 52.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
B. Jilma, S. Dallinger, N. Hergovich, H.-G. Eichler, V. Richter, and O. F. Wagner
Effects of Hyperinsulinemia on Plasma Levels of Circulating Adhesion Molecules
J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1748 - 1751.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
N.-G. Chen, M. Holmes, and G. M. Reaven
Relationship Between Insulin Resistance, Soluble Adhesion Molecules, and Mononuclear Cell Binding in Healthy Volunteers
J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3485 - 3489.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
B. Dugue, E. Leppanen, and R. Grasbeck
Preanalytical Factors (Biological Variation) and the Measurement of Serum Soluble Intercellular Adhesion Molecule-1 in Humans: Influence of the Time of Day, Food Intake, and Physical and Psychological Stress
Clin. Chem., September 1, 1999; 45(9): 1543 - 1547.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kautzky-Willer, A.
Right arrow Articles by Wagner, O. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kautzky-Willer, A.
Right arrow Articles by Wagner, O. F.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals